BCR and B-cell chronic lymphocytic leukemia: The efficacy of duvelisib monotherapy was confirmed in the phase III “DUO trial” comparing duvelisib to ofatumumab in 319 R/R CLL, excluding previously BCR inhibitors treated patients from trial [50].